Skip to main content
Log in

P2Y12 inhibition with aspirin or rivaroxaban: GEMINI-ACS-1 study

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. NCT02293395

References

  1. Ohman EM, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet : 18 Mar 2017. Available from: URL: http://doi.org/10.1016/S0140-6736(17)30751-1.

  2. Gurbel PA, et al. GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes. Lancet : 27 Mar 2017. Available from: URL: http://dx.doi.org/10.1016/ S0140-6736(17)30760-2.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

P2Y12 inhibition with aspirin or rivaroxaban: GEMINI-ACS-1 study. Reactions Weekly 1645, 12 (2017). https://doi.org/10.1007/s40278-017-28094-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-017-28094-9

Navigation